Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KLK14 | Q9P0G3 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18940545 | 0.85 | ACLY (0.52) | CYP11B1CYP11B2CYP3A4F2MAPT | |
| SCHEMBL27830572 | 0.85 | ACLY (0.47) | CYP11B1CYP11B2F2MAPTKMT2A | |
| SCHEMBL16760212 | 0.83 | NR1H2 (0.52) | — | |
| SCHEMBL7947787 | 0.80 | CYP2A6 (0.49) | CYP2A6MAOAMAOBCYP11B1CYP11B2 | |
| SCHEMBL16760311 | 0.76 | CYP11B1 (0.49) | CYP2A6MAOAMAOBCYP11B1CYP11B2 | |
| SCHEMBL9555552 | 0.75 | ACLY (0.47) | MAOAMAOBKMT2AKDM4EALDH1A1 | |
| SCHEMBL1605154 | 0.74 | ELANE (0.47) | CYP11B1CYP11B2F2MAPTKMT2A | |
| SCHEMBL1605932 | 0.73 | CYP11B2 (0.46) | CYP11B1CYP11B2F2MAPTKLK7 | |
| SCHEMBL28981312 | 0.71 | KDR (0.42) | MAOAMAOBKMT2AKDM4EALDH1A1 | |
| SCHEMBL16760261 | 0.71 | TTK (0.51) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3074385-B1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF PSYCHIATRIC AND NEUROLOGICAL CONDITIONS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-12-22 | — | — | EP | disclosed |
| US-10562882-B2 | Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-18 | — | — | US | disclosed |
| US-20170166553-A1 | Piperidine Derivatives for Use in the Treatment or Prevention of Psychiatric and Neurological Conditions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166553-A1 | Piperidine Derivatives for Use in the Treatment or Prevention of Psychiatric and Neurological Conditions | GRIN2C, GRIN2A, PNMT | CYP2A6 470/4885MAOA 105/4885MAOB 66/4885 |
| US-10562882-B2 | Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions | GRIN2C, GRIN2A, PNMT | CYP2A6 470/4885MAOA 105/4885MAOB 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.